共 50 条
- [31] A PHASE 2 STUDY OF THE HER2 ANTIBODY-DRUG CONJUGATE TRASTUZUMAB-DM1 (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH TRASTUZUMAB, LAPATINIB, AND CHEMOTHERAPYANNALS OF ONCOLOGY, 2010, 21 : 97 - 97Krop, I.LoRusso, P.Miller, K. D.Modi, S.Yardley, D.Rodriguez, G.Lu, M.Burington, B.Agresta, S.Rugo, H.
- [32] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United StatesDrugs - Real World Outcomes, 2023, 10 : 177 - 186Neelima DenduluriJanet L. EspiritoMichelle D. HackshawChuck WentworthTamy RecchiaWinghan J. Kwong
- [33] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United StatesDRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 177 - 186Denduluri, NeelimaEspirito, Janet L.Hackshaw, Michelle D.Wentworth, ChuckRecchia, TamyKwong, Winghan J.
- [34] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancerCancer Chemotherapy and Pharmacology, 2019, 84 : 175 - 185Dan LuChunze LiMatthew RiggsDaniel PolhamusJonathan FrenchPriya AgarwalShang-Chiung ChenShweta VadhavkarMonika PatreAlexander StrasakAngelica QuartinoJin Yan JinSandhya Girish
- [35] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancerCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 175 - 185Lu, DanLi, ChunzeRiggs, MatthewPolhamus, DanielFrench, JonathanAgarwal, PriyaChen, Shang-ChiungVadhavkar, ShwetaPatre, MonikaStrasak, AlexanderQuartino, AngelicaJin, Jin YanGirish, Sandhya
- [36] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastasesBREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318Jacot, WilliamPons, ElvireFrenel, Jean-SebastienGuiu, SeverineLevy, ChristelleHeudel, Pierre EtienneBachelot, ThomasD'Hondt, VeroniqueDarlix, AmelieFirmin, NellyRomieu, GillesThezenas, SimonDalenc, Florence
- [37] Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).CANCER RESEARCH, 2013, 73 (08)Baselga, JoseVerma, SunilRo, JungsilHuober, JensGuardino, EllieFang, LiangOlsen, StevenPhillips, Gail Lewisde Haas, SannePegram, Mark
- [38] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastasesBreast Cancer Research and Treatment, 2016, 157 : 307 - 318William JacotElvire PonsJean-Sébastien FrenelSéverine GuiuChristelle LevyPierre Etienne HeudelThomas BachelotVéronique D’HondtAmélie DarlixNelly FirminGilles RomieuSimon ThezenasFlorence Dalenc
- [39] A phase lb study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Waks, Adrienne GropperKeenan, TanyaLi, TianyuTayob, NabihahWulf, Gerburg M.Richardson, Edward T.Mittendorf, Elizabeth A.Overmoyer, BethKrop, Ian E.Winer, Eric P.Van Allen, Eliezer MendelAgudo, JudithTolaney, Sara M.
- [40] Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents Results From the T-PAS Expanded Access StudyCANCER JOURNAL, 2015, 21 (05): : 357 - 364Yardley, Denise A.Krop, Ian E.LoRusso, Patricia M.Mayer, MusaBarnett, BrianYoo, BonginPerez, Edith A.